Treating Dual Nicotine Users with Smoking Cessation Therapy

Jul.22.2022
A study from the University of Washington Medicine found that tobacco treatment can help dual smokers quit smoking.

Researchers at the University of Washington School of Medicine, led by Louis, have found that as smokers attempt to quit smoking, some turn to e-cigarettes. However, these individuals often become dual nicotine users, simultaneously smoking traditional cigarettes and e-cigarettes. The good news is that researchers have found that smoking cessation treatments that focus on nicotine replacement and counseling can help these dual users quit smoking.


The majority of the 40 million smokers in the United States admit to wanting to quit smoking. Some are turning to e-cigarettes as a step towards that goal. However, an increasing number of people are becoming dual nicotine users, smoking both traditional cigarettes and e-cigarettes.


Researchers have found that many people who try to quit smoking end up increasing their intake of nicotine instead. However, there is good news: a smoking cessation treatment that focuses on nicotine replacement and counseling, which has been approved by the US Food and Drug Administration (FDA), can help dual users quit smoking. In fact, this treatment appears to be effective for both dual users and those who only smoke traditional cigarettes.


The research findings were published in the "Thorax" journal on July 21st.


We suggest FDA-approved treatment methods such as nicotine replacement therapy, medication such as varenicline, and counseling for smokers. However, we are aware that an increasing number of people are using both cigarettes and e-cigarettes. The good news is that tobacco treatment can still help these individuals quit smoking and overcome their nicotine addiction." - Dr. Xunchen Li, Medical Doctor and Senior Researcher and Associate Professor in Psychiatry.


On average, about 70% of smokers attempt to quit smoking. Another 20% claim they want to smoke less. However, among those who have not received any treatment such as nicotine replacement therapy or counseling, only about 5% successfully quit smoking.


A review of the electronic health records of over 110,000 smokers who visited Barnes Jewish Hospital between 2018 and 2020 found that the number of electronic cigarette users had doubled. While some individuals may have started using e-cigarettes as a potential step towards quitting smoking, many seem to have become trapped. Rather than quitting, they began using electronic cigarettes while continuing to smoke traditional cigarettes.


In the course of the research, a growing number of relatively small but dual users of smoking were identified. Approximately 0.8% of individuals reported dual smoking in the first year of the study, but by the end of the data collection process, this figure had increased to 2.3%. The authors note that the actual number of dual users may be higher.


Researchers have discovered that around one in five (20.8%) dual users quit smoking within 12 months. In comparison, the quit rate for those who only smoke traditional cigarettes is 16.8%.


Treatment appears to still be the key for dual users. When they receive smoking cessation therapy, nearly one-third (29%) become non-smokers after 12 months. Among dual users who do not receive treatment, only about 17% are able to quit.


The first author, Dr. Brendan T., who is a surgical resident and thoracic surgery researcher, stated that although dual users have a higher quit rate, approximately two-thirds of individuals still smoke a year later, even after treatment. Additionally, due to limited knowledge regarding the long-term health effects of e-cigarette use, he advises against using e-cigarettes as a means to quit smoking.


Hayden stated that the current scientific consensus is that using both traditional cigarettes and e-cigarettes is detrimental to one's health. Although current guidelines do not recommend using e-cigarettes as a way to quit smoking, it has been found that among those who use both products, traditional tobacco treatments approved by the FDA, such as nicotine replacement therapy and behavioral support therapy, can help them quit smoking.


I apologize, but without context or specific text to work with, I am unable to complete this task. Please provide me with more information or a specific text that needs translation.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Charlie’s Plans Q3 2026 Pilot of America’s First Age-Gated Flavored Disposable Vape
Charlie’s Plans Q3 2026 Pilot of America’s First Age-Gated Flavored Disposable Vape
U.S. vape company Charlie’s Holdings announced plans to pilot its age-gated flavored disposable vape products in hundreds of retail stores during the third quarter of 2026. The company said the products will utilize AI- and blockchain-powered age-verification technology designed to address FDA concerns over youth access and potentially create a new compliance pathway for flavored vape products.
Jun.15
BAT Shares Surge Nearly 6% as FDA Policy Shift Eases Pressure on Vuse and Velo
BAT Shares Surge Nearly 6% as FDA Policy Shift Eases Pressure on Vuse and Velo
British American Tobacco (BAT) shares rose sharply on May 12 after the U.S. Food and Drug Administration signaled it would deprioritize enforcement against certain unauthorized e-cigarette and nicotine pouch products with accepted premarket applications. Investors viewed the move as favoring established players such as BAT’s Vuse and Velo brands.
BAT
May.13
Product | Geek Bar Expands Meloso Lineup With the Launch of Meloso Max 2
Product | Geek Bar Expands Meloso Lineup With the Launch of Meloso Max 2
Geek Bar has added Meloso Max 2 to its official product lineup, further expanding its disposable vape portfolio. As the latest generation of the Meloso series, the new device introduces upgrades in endurance, device interaction and industrial design while reinforcing Geek Bar’s strategy of offering differentiated disposable products across multiple usage scenarios.
Jun.26
French Vape Distributor Kumulus Vape Yields About 3% as Earnings Growth Stalls
French Vape Distributor Kumulus Vape Yields About 3% as Earnings Growth Stalls
Listed French vape distributor Kumulus Vape will trade ex-dividend on June 26, 2026, and pay an annual dividend of €0.10 per share on June 30, with Simply Wall St saying the payout is covered by profit and free cash flow, while weak earnings growth remains a concern.
Industry InsightMarketNews
Jun.24
Italian Court Ends Six-Year Cigarette Excise Dispute, Rejecting Damages Claim
Italian Court Ends Six-Year Cigarette Excise Dispute, Rejecting Damages Claim
Italy’s Lazio Regional Administrative Court has dismissed an appeal by Italian Tobacco Manufacturing and Manifattura Italiana Tabacco over the cigarette excise calculation mechanism, upholding the minimum tax burden rules and excluding compensation for smaller tobacco operators.
News
Jun.26 by 2Firsts Perspectives
FDA Grants MRTP Orders for 20 ZYN Nicotine Pouches
FDA Grants MRTP Orders for 20 ZYN Nicotine Pouches
The U.S. Food and Drug Administration (FDA) has issued modified risk granted orders to Swedish Match USA for 20 ZYN nicotine pouch products, allowing the already-authorized products to be marketed with a specific claim that using ZYN instead of cigarettes lowers the risk of mouth cancer, heart disease, lung cancer, stroke, emphysema and chronic bronchitis.
Jul.01